Status:
COMPLETED
Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Background: Bladder cancer is a common cancer in the U.S. Survival rates for metastatic bladder cancer have not gotten better for 15 years. Diagnosing and assessing the disease is important for treat...
Detailed Description
This protocol is a chart review of the diagnostic imaging and management of patients with metastatic bladder cancer who have undergone PET MRI. The study will involve only review of patient records an...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients with metastatic bladder cancer seen between 2013 and 2016 at the NIH Clinical Center.
- EXCLUSION CRITERIA:
- Patients who opted out of storage of specimens/data for future use on prior studies will be excluded from this study.
Exclusion
Key Trial Info
Start Date :
October 26 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 16 2018
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03327883
Start Date
October 26 2017
End Date
October 16 2018
Last Update
July 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892